09:00 - 09:15 Opening & Welcome
09:15 - 10:00 Keynote: Classification and epidemiology of secondary and therapy-related leukemias
- Coleman Lindsley (United States)
10:00 - 10:30 Coffee break
10:30 - 11:50 Session 1: Susceptibility and mechanisms of secondary leukemogenesis
- BM-failure syndromes
Carmelo Gurnari (Italy)
- DDX41 and other susceptibility genes
Marie Sebert (France)
- TP53 and other classifier mutations
Andrew Wei (Australia)
11:50 - 12:50 Oral Abstracts Session 1
12:50 - 14:20 Lunch break
13:20 - 14:20 Satellite Symposium
Breakout Sessions
14:20 - 15: 40 Breakout A: Drugs and diseases in th-related AML
- Solid tumors and PARPi
Elisabetta Todisco (Italy)
- Hematologic malignancies (topo-II inhibitors, lenalidomide, autologous transplantation)
Sylvain Garciaz (France)
- Secondary leukemias with recurrent genetic abnormalities
Richard Dillon (United Kingdom)
14:20 - 15: 40 Breakout B
- Quantitative dynamics for transformation of MDS to AML
Verena Korber (United Kingdom)
- AML microenvironment
Dominique Bonnet (United Kingdom)
- Modelling secondary AML using human iduced pluripotent stem cells
Eirini Papapetrou (United States)
15:40 - 16:00 Coffee break
16:00 - 17:20 Session 2: Mechanisms of clonal progression
- CHIP and clinical management
Kirsten Grønbæk (Denmark)
- Clonal trajectories from normal haemopoiesis to clonal haemopoiesis (CH and CCUS) to MDS and MPD and then to AML
Coleman Lindsley (United States)
- Progressive immune remodelling as haemopoiesis changes over time from normal haemopoiesis to sAML
Sharam Kordasti (United Kingdom)
17:20 - 18:20 Satellite Symposium
18:20 - 19:20 Welcome reception & poster walk
Back